ZANIDATAMAB for Gastrooesophageal reflux disease: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 7 adverse event reports in the FDA FAERS database where ZANIDATAMAB was used for Gastrooesophageal reflux disease.
Most Reported Side Effects for ZANIDATAMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 49 | 34.5% | 5 | 45 |
| Infusion related reaction | 17 | 12.0% | 0 | 14 |
| Sepsis | 9 | 6.3% | 2 | 9 |
| Hypokalaemia | 8 | 5.6% | 4 | 5 |
| Pneumonia | 8 | 5.6% | 1 | 8 |
| Cerebrovascular accident | 7 | 4.9% | 0 | 7 |
| Decreased appetite | 7 | 4.9% | 0 | 7 |
| Pneumonitis | 7 | 4.9% | 1 | 4 |
| Acute kidney injury | 6 | 4.2% | 1 | 4 |
| Vomiting | 6 | 4.2% | 1 | 6 |
| Asthenia | 5 | 3.5% | 0 | 5 |
| Nausea | 5 | 3.5% | 1 | 5 |
Other Indications for ZANIDATAMAB
Adenocarcinoma gastric (78)
Oesophageal adenocarcinoma (42)
Product used for unknown indication (7)
Prophylaxis (6)
Other Drugs Used for Gastrooesophageal reflux disease
RANITIDINE (141,291)
OMEPRAZOLE (28,339)
ESOMEPRAZOLE (27,743)
PANTOPRAZOLE (18,706)
LANSOPRAZOLE (17,671)
DEXLANSOPRAZOLE (5,185)
RABEPRAZOLE (1,689)
NEXIUM (1,209)
FAMOTIDINE (1,099)
VONOPRAZAN (766)